Utama › Neuroblastoma › Texas
Kajian klinikal Neuroblastoma di Texas
15 kajian untuk Neuroblastoma sedang mencari peserta di lokasi di Texas.
Bandar di Texas
Teks kajian rasmi (Bahasa Inggeris)
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- dan 10 lagi
Mengambil pesertaFasa 3
Sehingga umur 30 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06172296Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- University of Texas MD Anderson Cancer Center ( Site 1007), Houston
Mengambil pesertaFasa 1/2
6 Months – 25 Years · Semua jantina · Dikemas kini 17 Sep 2026 · NCT06395103Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
- Dell Children's Blood and Cancer Center, Austin
- Children's Medical Center, Dallas
Mengambil pesertaFasa 2
Sehingga umur 22 · Semua jantina · Dikemas kini 4 Sep 2026 · NCT02559778Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
- Children's Medical Center, Dallas
Mengambil pesertaFasa 1/2
Sehingga umur 26 · Semua jantina · Dikemas kini 3 Sep 2026 · NCT06465199Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
- Children's Medical Center, Dallas
Mengambil pesertaFasa 1/2
Sehingga umur 30 · Semua jantina · Dikemas kini 3 Sep 2026 · NCT06541262Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
- Dell Children's Blood and Cancer Center, Austin
- Children's Medical Center, Dallas
Mengambil pesertaFasa 2
Umur 1 hingga 21 · Semua jantina · Dikemas kini 3 Sep 2026 · NCT06540963Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- dan 8 lagi
Mengambil pesertaFasa 3
365 Days – 30 Years · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT03126916Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Mengambil pesertaFasa 1/2
12 Months – 30 Years · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT04851119Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
- Dell Children's Blood and Cancer Center, Austin
Mengambil pesertaFasa 2
12 Months – 21 Years · Semua jantina · Dikemas kini 12 Ogo 2026 · NCT05489887PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
- Texas Children's Hospital, Houston
Mengambil pesertaFasa 1/2
Umur 1 hingga 30 · Semua jantina · Dikemas kini 22 Jul 2026 · NCT06721689NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma
- Texas Children's Hospital, Houston
Mengambil pesertaFasa 1
Umur 1 hingga 24 · Semua jantina · Dikemas kini 21 Jul 2026 · NCT07211737NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
- University of Texas Southwestern, Dallas
- Cook Children's Medical Center, Fort Worth
Mengambil pesertaFasa 2
Umur 1 hingga 31 · Semua jantina · Dikemas kini 20 Jul 2026 · NCT06450041Neuroblastoma Biology Study
- University of Texas Southwestern, Dallas
- Cook Children's Medical Center - Fort Worth, Fort Worth
Mengambil pesertaKajian pemerhatian
31 Days – 99 Years · Semua jantina · Dikemas kini 23 Mac 2026 · NCT01587300Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma
- University of Texas Southwestern Medical Center, Dallas
Mengambil peserta
Sehingga umur 17 · Semua jantina · Dikemas kini 10 Feb 2026 · NCT06831552GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma
- Texas Children's Hospital, Houston
Mengambil pesertaFasa 1
Umur 1 hingga 21 · Semua jantina · Dikemas kini 19 Sep 2025 · NCT03294954Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.